Low-dose xenogeneic mesenchymal stem cells target canine osteoarthritis through systemic immunomodulation and homing
Charlotte Beerts1,2, Sarah Y Broeckx1, Eva Depuydt1,3
1Boehringer Ingelheim Veterinary Medicine Belgium, Noorwegenstraat 4, 9940, Evergem, Belgium.
Background:
As current therapies for canine osteoarthritis (OA) provide mainly symptomatic improvement and fail to address the complex pathology of the disease, mesenchymal stem cells (MSCs) offer a promising biological approach to address both aspects of OA through their immunomodulatory properties.
Methods:
This study aimed to investigate the safety and efficacy of xenogeneic MSCs in dogs with OA at different dose levels after intravenous injection. OA was surgically induced in the right stifle joint. Thirty-two male and female dogs were divided into three treatment groups and a control group. Regular general physical examinations; lameness, joint, radiographic, and animal caretaker assessments; pressure plate analyses; and blood analyses were performed over 42 days. At study end, joint tissues were evaluated regarding gross pathology, histopathology, and immunohistochemistry. In a follow-up study, the biodistribution of intravenously injected 99mTc-labeled equine peripheral blood-derived MSCs was evaluated over 24h in three dogs after the cruciate ligament section.
Results:
The dose determination study showed the systemic administration of ePB-MSCs in a canine OA model resulted in an analgesic, anti-inflammatory, and joint tissue protective effect associated with improved clinical signs and improved cartilage structure, as well as a good safety profile. Furthermore, a clear dose effect was found with 0.3 × 106 ePB-MSCs as the most effective dose. In addition, this treatment was demonstrated to home specifically towards the injury zone in a biodistribution study.
Conclusion:
This model-based study is the first to confirm the efficacy and safety of systemically administered xenogeneic MSCs in dogs with OA. The systemic administration of a low dose of xenogeneic MSCs could offer a widely accessible, safe, and efficacious treatment to address the complex pathology of canine OA and potentially slow down the disease progression by its joint tissue protective effect.
Insights
Systemic administration of xenogeneic mesenchymal stem cells (MSCs) effectively treats canine osteoarthritis (OA) by reducing inflammation and protecting joint tissues. A low dose of MSCs offers a safe and promising therapeutic option for dogs with OA.
Area of Science:
- Veterinary Medicine
- Regenerative Medicine
- Immunology
Background:
- Current canine osteoarthritis (OA) therapies offer limited symptomatic relief and do not address the disease's underlying pathology.
- Mesenchymal stem cells (MSCs) present a promising biological treatment for OA due to their immunomodulatory capabilities.
Purpose of the Study:
- To evaluate the safety and efficacy of xenogeneic MSCs administered intravenously in dogs with OA.
- To determine optimal dosage levels for MSC treatment in a canine OA model.
Main Methods:
- Surgically induced OA in canine stifle joints, followed by intravenous administration of MSCs at varying doses.
- Comprehensive assessments including physical examinations, lameness scoring, radiographic analysis, pressure plate analysis, and blood work over 42 days.
- Detailed evaluation of joint tissues (gross pathology, histopathology, immunohistochemistry) and biodistribution studies of labeled MSCs.
Main Results:
- Systemic administration of equine peripheral blood-derived MSCs (ePB-MSCs) demonstrated analgesic, anti-inflammatory, and joint protective effects in the canine OA model.
- Improved clinical signs, enhanced cartilage structure, and a favorable safety profile were observed.
- A dose-dependent effect was identified, with 0.3 × 10^6 ePB-MSCs being the most effective dose, and MSCs showed specific homing to the injury site.
Conclusions:
- This study provides the first evidence for the efficacy and safety of systemically administered xenogeneic MSCs in dogs with OA.
- Low-dose systemic xenogeneic MSC therapy offers a potentially accessible, safe, and effective treatment for canine OA.
- This approach may help manage OA pathology and slow disease progression through joint tissue protection.
More Related Videos
11:22Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
Published on: May 21, 2013
10:47Isolation and Cellular Phenotyping of Mesenchymal Stem Cells Derived from Synovial Fluid and Bone Marrow of Minipigs
Published on: July 2, 2016
